We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
个性化mRNA疫苗在胶质母细胞瘤中显示出42%的18个月无复发生存率。了解突破性JAMA研究的细节及该方法的前景。
